AstraZeneca‘s Crestor reduces risk of blood clots in the veins – A new analysis from the JUPITER study shows that CRESTOR® (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).
Abbott gets a boost with stent results –‘ drug-coated stent, Xience V, is significantly more effective than Corp.’s Taxus three years after implantation in an artery, according to new long-term data. The data, presented Sunday at the American College of Cardiology meeting in Orlando, Fla., come from a 300-patient, Abbott-sponsored international trial known as SPIRIT II. The data are the longest to date for Abbott’s market-leading stent. Boston Scientific also markets Xience, which was approved last year, under the name Promus.
TriLipix for cholesterol: looking good – A combination of Abbott Laboratories’ new TriLipix triglycerides medicine and a low dose of AstraZeneca Plc’s Crestor cholesterol drug proved better than the individual pills in helping improve heart risk factors, researchers said. The combination did significantly better at lowering bad LDL cholesterol and other blood fats called triglycerides, as well as raising levels of good HDL cholesterol in patients with complex lipid disorders.
PLUS – Eli Lilly on mega-mergers: No – “I think we are seeing deals that are really driven more by weakness than what I would describe as strong strategic combinations … That will improve short-term problems but fail to answer the long-term question of research productivity.”
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff